ADA 2022: Patients with T2D who received a treatment intervention powered by artificial intelligence achieved a remission rate of more than 80%.

ADA 2022: Reduction in risk of progression to type 2 diabetes of 60% was seen in STEP program clinical trial participants with overweight or obesity.

ADA 2022: "Breakthrough" findings may help to address the unmet need for additional treatment options for young patients with type 2 diabetes.

ADA 2022: Oral semaglutide may be particularly effective for T2D patients with HbA1c ≥9% and prescribed more frequently for these patients by primary care clinicians.

ADA 2022: The protective effect of finerenone on cardiovascular and renal outcomes was not affected by initial HbA1c levels or T2D duration in analysis of data from the FIDELITY pooled cohort.

The CDC raised its monkeypox alert to a level 2 on June 6, reporting more than 1000 cases worldwide and 25 infections confirmed in 12 US states and DC.

ADA 2022: Professor Hiddo Heerspink led the prespecified SURPASS-4 analysis that found tirzepatide associated with a 41% reduction in risk of a composite renal outcome.

ADA 2022: In a real-world study of nearly half a million adults with T2D followed for 5 years, the SGLT-2 inhibitor surpassed both other classes used in routine clinical care.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

ADA 2022: Younger age, insulin use, higher HbA1c, and higher diabetes distress were found to be associated with CGM uptake in prospective study.

ADA 2022: In a new literature review, 43% of studies included identified diabetes as a potent risk for developing post-acute sequelae of COVID-19.

ADA 2022: Tirzepatide led overall to weight loss of up to 22.5% of baseline body weight with persons taking the 15 mg dose losing an average of 52 pounds.

ADA 2022: Tirzepatide, a GIP/GLP-1 receptor agonist, reduced a composite of kidney events in patients with type 2 diabetes and at increased cardiovascular risk in an analysis of SURPASS-4.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Understanding the interplay between obesity and depression in children is key for clinicians to best advise this patient population. An overview, here.

DiabetesWise Pro lets clinicians compare diabetes devices for a specific patient and provides the steps for ordering the device based on insurance type.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

A man of about 40-years-old is seen in the ED for a possible drug overdose. He complains of low back pain and asks for medication. What's your diagnosis?

The Abbott FreeStyle Libre 3 is the smallest, thinnest, and most accurate 14-day CGM with a 7.9% MARD, the company says.

A new survey of youth aged 14 to 24 years provides significant support for integrating questions about social needs into routine clinical care.